AlphAIAlphAI — Financial news for AI agents
investing.comOCT 212 min read$AGMB

Agomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $35 price target for Agomab Therapeutics (AGMB) after a panel discussion at United European Gastroenterology Week. The stock trades at $8.73, with potential upside of over 300%. Analysts highlight the company's financial strength and the potential of its drug ontunisertib for fibrostenosing Crohn’s disease. Other analysts have also initiated coverage with positive ratings and price targets.

Original reporting
investing.com
Published Oct 21, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AGMB
Bullish
medium confidence
Mentioned
$AGMB
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AGMBBullishMed
01

Why it matters

Analyst coverage reiteration with a $35 target suggests a significant upside from the current $8.73 price.

02

Market read

The new rating and price target could attract short‑term buying pressure in AGMB and influence sentiment in the niche fibrosis‑focused biotech space.

03

What to watch

Potential regulatory hurdles and competition from larger players in Crohn's disease treatments.

Relevance 6/10Novelty 5/10Timing: today

Background

Agomab Therapeutics presented Phase 2a STENOVA trial results at UEG Week, prompting analyst coverage updates.

Company-level read

Ticker impact

$AGMBBullishMedium confidence
Context

H.C. Wainwright reiterated a Buy rating and set a $35 price target for Agomab Therapeutics after a panel discussion on its Phase 2a STENOVA trial data.

Expected impact

likely upward pressure as investors price in the new $35 target

Evidence & confidence

The reiteration adds a concrete valuation and highlights clinical progress, prompting potential demand.

Market effects

Sector

Positive sentiment may spill over to other biotech firms developing fibrosis therapies.

Regional

U.S. biotech sector could see modest uplift.

Global

Limited to investors tracking early‑stage biotech pipelines.

Counterpoint

What could challenge this read

The rating may be premature given the early‑stage nature of the data and lack of long‑term efficacy evidence.

Key entities

  • company
    Agomab Therapeutics

    Biotech developing ontunisertib for fibrostenosing Crohn's disease.

  • analyst_firm
    H.C. Wainwright

    Equity research firm that reiterated a Buy rating on AGMB.

Read at source← All news

Related articles

OCT 14
$AGMBMedAI 8/10

Agomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's Disease

AgomAb Therapeutics (AGMB) dosed the first patient in a Phase 2b trial of Ontunisertib for Crohn's disease. The trial aims to enroll 320 adults with symptomatic fibrostenosing Crohn's disease across multiple countries. Ontunisertib has FDA Fast Track Designation and showed positive results in an earlier Phase 2a trial. The study's primary endpoint is endoscopic passability of ileal strictures at Week 24.

rttnews.com2 min
OCT 13
$AGMBMedAI 8/10

Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease

Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.

tipranks.com1 min
OCT 8
LowAI 8/10

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.

globenewswire.com2 min
OCT 2
$AGMBMedAI 8/10

H.C. Wainwright reiterates Agomab stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.

investing.com2 min
OCT 1
$AGMBMedAI 8/10

Why is Agomab Therapeutics stock sliding today?

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

investing.com2 min
OCT 1
$AGMBHighAI 8/10

Agomab stock jumps on positive trial data

Agomab Therapeutics (NASDAQ:AGMB) shares rose 6.3% premarket after positive trial data for ontunisertib in Crohn's disease. The STENOVA extension study showed favorable safety, low event rates, and sustained disease control. 97% of patients were in remission at Week 48. The company plans a Phase 2b study. Ontunisertib has FDA Fast Track Designation.

investing.com2 min